Searched for
PATHLABS EXECUTIVE
Smallcaps rally! IIFL Finance, Hindustan Copper, Meesho, other stocks jump up to 7%Smallcap stocks, including IIFL Finance, Meesho, and GRSE, surged up to 7% on Wednesday, outperforming benchmark indices. This rally occurr...- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Smallcaps continue to draw domestic flows, stock selection key: Sandip SabharwalIndian equity markets show resilience post-election results. Market expert Sandip Sabharwal notes that governance and policy continuity are...
- Forget the noise: These 54 smallcap stocks attracted FII buying in March quarterForeign institutional investors are strategically buying into beaten-down smallcap stocks in India, increasing stakes in 54 companies despi...
- Dr Lal PathLabs Q1 Results: Profit rises 28% to Rs 106 crore on strong testing demand, beats estimatesConsolidated net profit rose 28% to 1.06 billion rupees (around $13 million) for the quarter ended June 30, beating analysts' estimate of 9...
- Dr. LalPath Labs Q4 Reslts: Firm posts higher profit on healthy testing demandIts shares climbed as much as 7.8% after the results before trimming some gains to trade up about 6%. Rival Metropolis Healthcare was up ab...
- Hot Stocks: Brokerages view on Indian Hotels, Titan Company, Paytm and Dr Lal PathLabsGoldman Sachs maintained a sell rating on Dr Lal PathLabs with a target price of Rs 2200. The company reported a subdued volume growth and ...
- Fundamental Radar: Why Vijaya Diagnostic is poised to outperform peers? Sandeep Raina explainsThe company finds its niche in its radiology play, which contributes 36% to the overall revenue, and high B2C share and investments in late...
- Buy Dr. Lal Pathlabs, target price Rs 3525: ICICI SecuritiesDr. Lal Pathlabs Ltd., incorporated in the year 1995, is a Mid Cap company (having a market cap of Rs 23488.67 Crore) operating in Hospital...
- Dr Lal PathLabs Q2 results: Net profit up 11% at Rs 96 croreOperating revenue of the company increased by 15.4 per cent in Q2 FY22 to Rs 498.4 crore as compared with Rs 431.9 crore in Q2 FY21, Dr Lal...
- Dr Lal PathLabs Q2 net up 11 pc at Rs 96 cr; to acquire Suburban DiagnosticsDiagnostic services provider Dr Lal PathLabs on Tuesday posted a 10.6 per cent increase in its consolidated profit after tax (PAT) at Rs 96...
- Dr Lal PathLabs Q4 results: Net profit jumps over 2.5 times to Rs 85 crIts consolidated revenue from operations stood at Rs 431 crore for the quarter under consideration. It was Rs 301.7 crore for the same peri...
- Dr Lal PathLabs Q2 results: Net profit up 7.5% to Rs 87 crRevenue from operations stood at Rs 431.9 crore for the quarter under consideration. It was Rs 365.6 crore for the same period a year ago, ...
- Dr Lal PathLabs Q1 results: Net profit declines 52% to Rs 28.4 croreThe company had posted a net profit of Rs 59.1 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing ...
- Outlook for diagnostics industry favourable for growth: Dr Lal PathLabsThe company said it served 1.94 crore patients and processed 4.77 crore samples
- Dr Lal PathLabs Q4 results: Net profit declines 31% to Rs 32.6 croreThe company had posted a net profit of Rs 47.4 crore for the corresponding period of previous fiscal.
- Stock pick of the week: Find out what makes Dr Lal Pathlabs a good buyBright sectoral prospects and valuation below its brief trading history multiple, has made the firm analysts’ top pick.
- Dr Lal PathLabs IPO to hit markets soonLeading diagnostic chain Dr Lal PathLabs, which has received capital markets regulator Sebi's approval to raise funds, hopes to launch an i...
- Dr Lal PathLabs may make public market debut next fiscalDr Lal PathLabs is undertaking a restructuring exercise to determine the issue size of its potential IPO and a decision is expected by Dece...
- US PE firm in talks to buy 15% in Dr Lal PathLabs from SequoiaUS-based private equity (PE) firm TA Associates is in advanced talks to buy half of Sequoia Capital’s 30% stake in the country’s largest di...
Load More
